A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients from 1 Year to Less Than 18 Years Old Hospitalized with COVID-19
Latest Information Update: 01 Oct 2024
At a glance
- Drugs Baricitinib (Primary)
- Indications COVID 2019 infections; COVID-19 respiratory infection
- Focus Pharmacokinetics; Registrational
- Acronyms COV-BARRIER; COV-BARRIER-PEDS
- Sponsors Eli Lilly and Company
- 01 Aug 2024 Planned End Date changed from 30 Aug 2024 to 1 Dec 2024.
- 01 Aug 2024 Planned primary completion date changed from 14 Jul 2024 to 1 Dec 2024.
- 14 Sep 2023 Planned End Date changed from 30 Aug 2023 to 30 Aug 2024.